242 related articles for article (PubMed ID: 32665367)
1. Oral immunotherapy for treatment of peanut allergy.
Dunlop JH
J Investig Med; 2020 Aug; 68(6):1152-1155. PubMed ID: 32665367
[TBL] [Abstract][Full Text] [Related]
2. Peanut Oral Immunotherapy: a Current Perspective.
Patrawala M; Shih J; Lee G; Vickery B
Curr Allergy Asthma Rep; 2020 Apr; 20(5):14. PubMed ID: 32314071
[TBL] [Abstract][Full Text] [Related]
3. AR101 Oral Immunotherapy for Peanut Allergy.
; Vickery BP; Vereda A; Casale TB; Beyer K; du Toit G; Hourihane JO; Jones SM; Shreffler WG; Marcantonio A; Zawadzki R; Sher L; Carr WW; Fineman S; Greos L; Rachid R; Ibáñez MD; Tilles S; Assa’ad AH; Nilsson C; Rupp N; Welch MJ; Sussman G; Chinthrajah S; Blumchen K; Sher E; Spergel JM; Leickly FE; Zielen S; Wang J; Sanders GM; Wood RA; Cheema A; Bindslev-Jensen C; Leonard S; Kachru R; Johnston DT; Hampel FC; Kim EH; Anagnostou A; Pongracic JA; Ben-Shoshan M; Sharma HP; Stillerman A; Windom HH; Yang WH; Muraro A; Zubeldia JM; Sharma V; Dorsey MJ; Chong HJ; Ohayon J; Bird JA; Carr TF; Siri D; Fernández-Rivas M; Jeong DK; Fleischer DM; Lieberman JA; Dubois AEJ; Tsoumani M; Ciaccio CE; Portnoy JM; Mansfield LE; Fritz SB; Lanser BJ; Matz J; Oude Elberink HNG; Varshney P; Dilly SG; Adelman DC; Burks AW
N Engl J Med; 2018 Nov; 379(21):1991-2001. PubMed ID: 30449234
[TBL] [Abstract][Full Text] [Related]
4. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
[TBL] [Abstract][Full Text] [Related]
5. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
[TBL] [Abstract][Full Text] [Related]
6. Peanut gastrointestinal delivery oral immunotherapy in adolescents: Results of the build-up phase of a randomized, double-blind, placebo-controlled trial (PITA study).
Fauquert JL; Michaud E; Pereira B; Bernard L; Gourdon-Dubois N; Rouzaire PO; Rochette E; Merlin E; Evrard B;
Clin Exp Allergy; 2018 Jul; 48(7):862-874. PubMed ID: 29665158
[TBL] [Abstract][Full Text] [Related]
7. Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial.
Michaud E; Evrard B; Pereira B; Rochette E; Bernard L; Rouzaire PO; Gourdon-Dubois N; Merlin E; Fauquert JL
Trials; 2015 Apr; 16():197. PubMed ID: 25925398
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.
Bird JA; Spergel JM; Jones SM; Rachid R; Assa'ad AH; Wang J; Leonard SA; Laubach SS; Kim EH; Vickery BP; Davis BP; Heimall J; Cianferoni A; MacGinnitie AJ; Crestani E; Burks AW;
J Allergy Clin Immunol Pract; 2018; 6(2):476-485.e3. PubMed ID: 29092786
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
[TBL] [Abstract][Full Text] [Related]
10. Current opinion and review on peanut oral immunotherapy.
Deol S; Bird JA
Hum Vaccin Immunother; 2014; 10(10):3017-21. PubMed ID: 25483680
[TBL] [Abstract][Full Text] [Related]
11. Probiotic peanut oral immunotherapy is associated with long-term persistence of 8-week sustained unresponsiveness and long-lasting quality-of-life improvement.
Loke P; Hsiao KC; Lozinsky AC; Ashley SE; Lloyd M; Pitkin S; Axelrad CJ; Jayawardana KS; Tey D; Su EL; Robinson M; Leung ASY; Dunn Galvin A; Tang MLK
Clin Exp Allergy; 2022 Jun; 52(6):806-811. PubMed ID: 35485166
[No Abstract] [Full Text] [Related]
12. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
Fernandez-Rivas M; Vereda A; Vickery BP; Sharma V; Nilsson C; Muraro A; Hourihane JO; DunnGalvin A; du Toit G; Blumchen K; Beyer K; Smith A; Ryan R; Adelman DC; Jones SM
Allergy; 2022 Mar; 77(3):991-1003. PubMed ID: 34320250
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy approaches for peanut allergy.
Kim EH; Patel C; Burks AW
Expert Rev Clin Immunol; 2020 Feb; 16(2):167-174. PubMed ID: 31928251
[No Abstract] [Full Text] [Related]
14. Peanut allergy and oral immunotherapy.
Lee TH; Chan JKC; Lau PC; Luk WP; Fung LH
Hong Kong Med J; 2019 Jun; 25(3):228-234. PubMed ID: 31178442
[TBL] [Abstract][Full Text] [Related]
15. Peanut Oral Immunotherapy: State of the Art.
Tang MLK; Lozinsky AC; Loke P
Immunol Allergy Clin North Am; 2020 Feb; 40(1):97-110. PubMed ID: 31761124
[TBL] [Abstract][Full Text] [Related]
16. Update on peanut allergy: Prevention and immunotherapy.
Cook QS; Kim EH
Allergy Asthma Proc; 2019 Jan; 40(1):14-20. PubMed ID: 30582491
[No Abstract] [Full Text] [Related]
17. Peanut Allergen Powder (Palforzia) for Peanut Allergy.
Erlich D
Am Fam Physician; 2022 Jan; 105(1):20-21. PubMed ID: 35029941
[No Abstract] [Full Text] [Related]
18. Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results.
Fleischer DM; Shreffler WG; Campbell DE; Green TD; Anvari S; Assa'ad A; Bégin P; Beyer K; Bird JA; Brown-Whitehorn T; Byrne A; Chan ES; Cheema A; Chinthrajah S; Chong HJ; Davis CM; Ford LS; Gagnon R; Greenhawt M; Hourihane JO; Jones SM; Kim EH; Lange L; Lanser BJ; Leonard S; Mahler V; Maronna A; Nowak-Wegrzyn A; Oriel RC; O'Sullivan M; Petroni D; Pongracic JA; Prescott SL; Schneider LC; Smith P; Staab D; Sussman G; Wood R; Yang WH; Lambert R; Peillon A; Bois T; Sampson HA
J Allergy Clin Immunol; 2020 Oct; 146(4):863-874. PubMed ID: 32659313
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of allergen-specific immunotherapy for peanut allergy: a meta-analysis of randomized controlled trials.
Sun J; Hui X; Ying W; Liu D; Wang X
Allergy Asthma Proc; 2014; 35(2):171-7. PubMed ID: 24717795
[TBL] [Abstract][Full Text] [Related]
20. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety.
Chu DK; Wood RA; French S; Fiocchi A; Jordana M; Waserman S; Brożek JL; Schünemann HJ
Lancet; 2019 Jun; 393(10187):2222-2232. PubMed ID: 31030987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
